News | January 27, 2023
Torrent Pharmaceuticals posts Q3FY23 consolidated PAT at Rs. 283 Cr
The company has reported total income of Rs. 2481 crores during the period ended December 31, 2022
The company has reported total income of Rs. 2481 crores during the period ended December 31, 2022
The scheme is subject to statutory and regulatory approvals as may be necessary.
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
The consideration includes Rs. 115 crore (on the date of signing) of cash and cash equivalents in the acquired business indicating an Enterprise Value of Rs. 1,885 crore
Torrent Pharmaceuticals has reported total income of Rs. 2377 crores during the period ended June 30, 2022.
The integration and transition of the brands are expected to be completed by June 2022.
Torrent Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.
DCGI approved the drug based on the review of clinical data
Torrent Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
Torrent is one of India's fastest-growing pharma majors
Subscribe To Our Newsletter & Stay Updated
